1
|
Koell B, Ludwig S, Weimann J, Waldschmidt L, Schirmer J, Reichenspurner H, Blankenberg S, Conradi L, Schofer N, Kalbacher D. C-Reactive Protein to Albumin Ratio offers superior risk prediction in patients undergoing mitral valve edge-to-edge repair: a comparison to established surgical risk scores. Eur Heart J 2022. [DOI: 10.1093/eurheartj/ehac544.1641] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
The population of patients with relevant mitral regurgitation (MR) who stand to gain optimal benefit from mitral valve transcatheter edge-to-edge repair (TEER) remains to be determined. Prior to TEER, a heart-team approach with interdisciplinary decision-making is mandatory integrating both the patient profile and relevant co-morbidities. In addition, the application of established surgical risk scores is recommended by current guidelines. Whether alternative risk prediction is more suitable for this fragile patient cohort burdened with various co-morbidities has not been examined in detail. A simplified approach may be achieved by using the C-Reactive Protein to Albumin Ratio (CAR), but its value in TEER is unclear.
Methods
This single-center, retrospective study thought to determine long-term prognostic accuracy of different risk scores in patients with relevant MR undergoing TEER. For this analysis, 316 patients with a median follow-up time of 5.81 years were included. The primary outcome measure was defined as all-cause mortality. ROC analysis was conducted for the identification of the optimal CAR threshold, subsequently dichotomizing patients into two groups (CAR ≤0.4 and CAR >0.4) estimating their long-term event rate using the Kaplan-Meier method. In addition, we evaluated the prognostic value of CAR compared to two conventional surgical risk scores (logistic EuroSCORE and Society of Thoracic Surgeons [STS] risk score) using C-Index analysis.
Results
Among 316 high-risk patients undergoing TEER (mean age 75.6±8.2 years, 61.7% male, median logistic EuroSCORE 19.9% [11.7; 31.6], median STS Score 3.8% [2.2; 5.7]), 176 (55.7%) patients had a CAR value ≤0.4. Patients with an elevated CAR (>0.4) predominantly suffered from a higher burden of co-morbidities, such as peripheral artery disease (p=0.001), chronic obstructive pulmonary disease (p=0.044), and chronic kidney disease (p=0.015). Consequently, these patients had significantly higher logistic EuroSCORE and STS Score than patients with CAR ≤0.4 (logistic EuroSCORE p=0.002; STS Score p<0.001). Stratification according to the CAR threshold of 0.4 led to significant differences in the Cumulative Incidence curves (p<0.001). In addition, log-rank test revealed a superior risk stratification of the simplified CAR approach compared to established surgical risk scores (Figure 1). This effect consequently reflects in a higher adjusted C-Index for CAR (0.608) compared to logistic EuroSCORE (0.502; p<0.001) and STS Score (0.498; p<0.001).
Conclusions
Our data provide first evidence that alternative risk prediction using CAR allows for a feasible and easy-to-use risk prediction in a real-word TEER cohort presenting with advanced age, a high proportion of frailty and numerous co-morbidities. Alternative risk prediction in TEER patients should be investigated in more detail as the established surgical risk scores seem to demonstrate limited applicability in patients scheduled for TEER.
Funding Acknowledgement
Type of funding sources: Public Institution(s). Main funding source(s): University Medical Center Hamburg-Eppendorf, Hamburg, Germany
Collapse
Affiliation(s)
- B Koell
- University Heart & Vascular Center Hamburg, Department of Cardiology , Hamburg , Germany
| | - S Ludwig
- University Heart & Vascular Center Hamburg, Department of Cardiology , Hamburg , Germany
| | - J Weimann
- University Heart & Vascular Center Hamburg, Department of Cardiology , Hamburg , Germany
| | - L Waldschmidt
- University Heart & Vascular Center Hamburg, Department of Cardiology , Hamburg , Germany
| | - J Schirmer
- University Heart & Vascular Center Hamburg, Department for Cardiovascular Surgery , Hamburg , Germany
| | - H Reichenspurner
- University Heart & Vascular Center Hamburg, Department for Cardiovascular Surgery , Hamburg , Germany
| | - S Blankenberg
- University Heart & Vascular Center Hamburg, Department of Cardiology , Hamburg , Germany
| | - L Conradi
- University Heart & Vascular Center Hamburg, Department for Cardiovascular Surgery , Hamburg , Germany
| | - N Schofer
- University Heart & Vascular Center Hamburg, Department of Cardiology , Hamburg , Germany
| | - D Kalbacher
- University Heart & Vascular Center Hamburg, Department of Cardiology , Hamburg , Germany
| |
Collapse
|
2
|
Ludwig S, Sedighian S, Weimann J, Koell B, Waldschmidt L, Schaefer A, Seiffert M, Westermann D, Reichenspurner H, Blankenberg S, Schofer N, Lubos E, Conradi L, Kalbacher D. Outcomes of patients with severe mitral regurgitation treated with transcatheter mitral valve implantation or medical therapy. Eur Heart J Cardiovasc Imaging 2022. [DOI: 10.1093/ehjci/jeab289.363] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Funding Acknowledgements
Type of funding sources: None.
Background
Patients with severe mitral regurgitation (MR) unsuitable for standard therapy (i.e., open-heart surgery and transcatheter edge-to-edge repair [TEER]), often remain on medical therapy (MT) alone. Transcatheter mitral valve implantation (TMVI) may represent an alternative treatment option for these patients.
Purpose
We aimed to investigate differences in anatomical baseline characteristics and echocardiographic outcomes between MR patients unsuitable for standard therapy, that were either treated with TMVI or remained on MT.
Methods
Between 05/2016-02/2021, 121 high-risk patients with severe MR were evaluated for TMVI. Clinical, echocardiographic and functional outcomes between the subgroups of patients treated with TMVI and MT were compared. The primary combined endpoint was all-cause death or heart failure (HF) hospitalization at 1 year. Subgroup analyses were performed to define specific patient subsets favouring either TMVI or MT.
Results
At baseline, there were no differences between the TMVI group (n = 38) and the MT group (n = 44) regarding age (all TMVI vs. MT: 77.0 years [IQR 72.9, 80.1] vs. 79.0 [IQR 76.0, 81.7], p = 0.13), gender (42.1% female vs. 56.8% female, p = 0.27) and estimated surgical risk (EuroSCORE II 4.4% [IQR 2.8, 13.6] vs. 6.4 [IQR 3.4, 10.1], p = 0.72). Patients undergoing TMVI were more frequently treated for secondary MR (68.4%), while primary MR was the most prevalent MR etiology in patients remaining on medical therapy (50.0%). Left ventricular (LV) end-diastolic diameters (LVEDD) were larger and LV ejection fraction (LVEF) was lower in the TMVI group (LVEDD 58.0mm [IQR 51.4, 65.0], LVEF 37.0% [IQR 31.4, 51.2]) compared to the MT group (LVEDD 52.0mm [IQR 46.2, 58.8], LVEF 54.5% [IQR 40.8, 60.0]) (p = 0.02 for LVEDD, p < 0.001 for LVEF). MR was effectively reduced to ≤ mild MR in all patients undergoing TMVI. In the MT group, MR remained severe in 90% of patients after 1 year. The primary composite endpoint occurred numerically more often in the MT group (72.2%) compared to the TMVI group (51.6%, p = 0.061). Regarding the primary endpoint, the subgroups of patients with LVEF 30-49% (HR 0.28 [95%-CI 0.11-0.67], p = 0.004), effective regurgitant orifice area (EROA) <0.4 cm2 (HR 0.30 [95%-CI 0.13-0.71], p = 0.006), tricuspid annular plane systolic excursion (TAPSE) ≥17mm (HR 0.27 [95%-CI 0.11-0.67], p = 0.005) and New York Heart Association functional class III (HR 0.38 [95%-CI 0.18-0.81], p = 0.012) were more likely to benefit from TMVI compared to MT.
Conclusions
In patients with severe MR unsuitable for standard therapy, TMVI represents a reasonable therapeutic alternative yielding effective elimination of MR. While most patients eligible for TMVI suffer from secondary MR, the majority of patients remaining on MT has primary MR. The primary endpoint occurred numerically, yet not statistically, more often in patients on MT. Baseline echocardiography was able to identify subgroups of patients with beneficial outcome after TMVI.
Collapse
Affiliation(s)
- S Ludwig
- University Heart & Vascular Center Hamburg, Hamburg, Germany
| | - S Sedighian
- University Heart & Vascular Center Hamburg, Hamburg, Germany
| | - J Weimann
- University Heart & Vascular Center Hamburg, Hamburg, Germany
| | - B Koell
- University Heart & Vascular Center Hamburg, Hamburg, Germany
| | - L Waldschmidt
- University Heart & Vascular Center Hamburg, Hamburg, Germany
| | - A Schaefer
- University Heart & Vascular Center Hamburg, Hamburg, Germany
| | - M Seiffert
- University Heart & Vascular Center Hamburg, Hamburg, Germany
| | - D Westermann
- University Heart & Vascular Center Hamburg, Hamburg, Germany
| | | | - S Blankenberg
- University Heart & Vascular Center Hamburg, Hamburg, Germany
| | - N Schofer
- University Heart & Vascular Center Hamburg, Hamburg, Germany
| | - E Lubos
- University Heart & Vascular Center Hamburg, Hamburg, Germany
| | - L Conradi
- University Heart & Vascular Center Hamburg, Hamburg, Germany
| | - D Kalbacher
- University Heart & Vascular Center Hamburg, Hamburg, Germany
| |
Collapse
|
3
|
Grundmann D, Linder M, Gossling A, Voigtlaender L, Ludwig S, Waldschmidt L, Demal T, Bhadra O, Seiffert M, Schaefer A, Reichenspurner H, Blankenberg S, Westermann D, Conradi L, Schofer N. Diagnostic value and prognostic impact of various invasively derived hemodynamic parameters in patients with severe aortic stenosis undergoing TAVI. Eur Heart J 2021. [DOI: 10.1093/eurheartj/ehab724.1620] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
Ejection time (ET) and Acceleration time (AT) have been described as echocardiographic markers for aortic stenosis (AS).1 Moreover, in a recent study time between invasively measured left ventricular and aortic systolic pressure peaks (T-LVAo) was associated with anatomic AS severity.2 However, the diagnostic value of these parameters has not been validated in a larger patient cohort and their prognostic impact in AS patients undergoing transcatheter aortic valve implantation (TAVI) remains unknown.
Purpose
We aimed to assess the diagnostic value and prognostic impact of ET, AT, and T-LVAo as assessed by invasive measurements in patients undergoing TAVI for severe AS.
Methods
This retrospective single-centre analysis studied 1478 patients undergoing TAVI from 2014 to 2019 for severe AS. All patients received echocardiographic, multislice computed tomography (MSCT) and invasive hemodynamic evaluation with simultaneous pressure measurements in left ventricle and aorta prior to TAVI. Anatomic AS severity was assessed according to MSCT-derived aortic valve calcification density (AVCd) defined as calcium volume per annulus area. All hemodynamic parameters were calculated offline using a dedicated software.
Results
Median patients' age was 81.2 (76.8–84.7) years and 807 (54.6%) were women. Predicted operative risk for mortality was 3.8 (2.6–5.7)% according to STS Score. Medians of invasively derived parameters were 70.0 ms (46.0–98.0) for T-LVAo, 308.0 ms (276.0–336.0) for ET, 180.0 ms (146.0–206.0) for AT. In spline analysis correlation of T-LVAo (Spearman: r=0.35; p<0.001) and ET (Spearman: r=0.18; p<0.001) with AVCd was significant but weak. AT showed negligible correlation with ACVd (Spearman: r=−0.05; p=0.089). The optimal cutoff for death (CD) according to C-statistic was 274 ms for ET and 158 ms for AT. Patients with ET or AT ≥ CD showed lower short and mid-term mortality rates compared to patients with ET or AT < CD (ET ≥ vs. < CD: mortality at 1-year: 14.5 vs. 31.9%, 3-years: 28.3 vs. 53.5%, all p<0.001; AT ≥ vs < CD: mortality at 1-year: 15.5 vs. 25.9%, p<0.001, 3-years: 34.0 vs. 41.0%, p=0.0032). Moreover, multivariate analysis for mortality identified ET (HR 0.58 [95% CI 0.43–0.77; p<0.001]) and AT (HR 0.65 [95% CI 0.49–0.86; p=0.0027]) to be associated with beneficial outcome after TAVI, independent from clinical risk factors and echocardiography-derived parameters like LVEF, mean gradient or stroke volume index. In contrast, T-LVAo showed no prognostic impact according to uni- or multivariate analyses.
Conclusion
T-LVAo provides the highest diagnostic value among the investigational hemodynamic parameters, however correlation with AVCd was weak. ET and AT are strong independent outcome predictors beyond clinical risk factors and standard echocardiographic parameters in AS patients following TAVI. Accordingly, use of ET and AT might improve risk assessment in patients scheduled for TAVI.
Funding Acknowledgement
Type of funding sources: None.
Collapse
Affiliation(s)
- D Grundmann
- University Heart Center Hamburg, Hamburg, Germany
| | - M Linder
- University Heart Center Hamburg, Hamburg, Germany
| | - A Gossling
- University Heart Center Hamburg, Hamburg, Germany
| | | | - S Ludwig
- University Heart Center Hamburg, Hamburg, Germany
| | | | - T Demal
- University Heart Center Hamburg, Hamburg, Germany
| | - O Bhadra
- University Heart Center Hamburg, Hamburg, Germany
| | - M Seiffert
- University Heart Center Hamburg, Hamburg, Germany
| | - A Schaefer
- University Heart Center Hamburg, Hamburg, Germany
| | | | | | - D Westermann
- University Heart Center Hamburg, Hamburg, Germany
| | - L Conradi
- University Heart Center Hamburg, Hamburg, Germany
| | - N Schofer
- University Heart Center Hamburg, Hamburg, Germany
| |
Collapse
|
4
|
Koell B, Ludwig S, Weimann J, Waldschmidt L, Schofer N, Seiffert M, Schirmer J, Westermann D, Reichenspurner H, Blankenberg S, Lubos E, Conradi L, Kalbacher D. Long-Term survival and functional status in patients with elevated mitral valve pressure gradient after transcatheter mitral valve repair. Eur Heart J 2021. [DOI: 10.1093/eurheartj/ehab724.1641] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
A growing number of patients are currently treated for severe mitral regurgitation (MR) using a transcatheter mitral valve repair (TMVr). In clinical routine, the potential risk of elevated post-procedural mitral valve pressure gradient (MPG) may prohibit optimal MR reduction driven by the avoidance of additional clip implantations. Thus, the unfavorable impact on survival and functional outcome of increased MPG in patients undergoing TMVr is currently debatable.
Methods
In this single-center, prospective study, survival and functional outcome of 780 consecutive patients with severe MR undergoing TMVr between September 2008 and January 2020 were investigated. After exclusion of patients with unsuccessful procedure and those lost to follow-up, data of 676 patients with a median follow-up time of 5.26 (5.11, 5.51) years were analyzed. MPG was determined by transthoracic echocardiography at discharge and considered elevated in excess of 4.5 mmHg. Kaplan-Meier analysis as well as multivariable Cox regression models were performed for the impact on elevated MPG on 5-year outcomes for the subgroups of functional MR (FMR) and degenerative MR (DMR). The primary outcome measure was a combined endpoint of death or rehospitalization for congestive heart failure.
Results
Among 676 patients undergoing TMVr (mean age 74.6±8.5 years, 59.0% male, median STS Score 3.9 [interquartile range 2.5; 6.0]), 179 (26.4%) patients had elevated MPG >4.5 mmHg. FMR was present in 426 (63.0%) patients. In the overall patient cohort, Kaplan-Meier and Cox Regression analyses could not demonstrate significant differences for the combined endpoint (p=0.99). In contrast, subgroup analysis according to MR etiology indicated a significant adverse influence of elevated MPG on the combined endpoint as well as functional outcome in patients with DMR, but not with FMR (Figure 1). After adjustment, multivariate Cox Regression analysis showed an inferior prognosis in patients with DMR and elevated MVPG >4.5 mmHg (hazard ratio 1.79 [1.17, 2.72], p=0.0069, Figure 2).
Conclusions
TMVr-patients with DMR and measurable elevated post-procedural MVPG face an inferior prognosis and reduced functional outcomes compared to patients with FMR.
Funding Acknowledgement
Type of funding sources: None. Figure 1Figure 2
Collapse
Affiliation(s)
- B Koell
- University Heart & Vascular Center Hamburg, Department of Cardiology, Hamburg, Germany
| | - S Ludwig
- University Heart & Vascular Center Hamburg, Department of Cardiology, Hamburg, Germany
| | - J Weimann
- University Heart & Vascular Center Hamburg, Department of Cardiology, Hamburg, Germany
| | - L Waldschmidt
- University Heart & Vascular Center Hamburg, Department of Cardiology, Hamburg, Germany
| | - N Schofer
- University Heart & Vascular Center Hamburg, Department of Cardiology, Hamburg, Germany
| | - M Seiffert
- University Heart & Vascular Center Hamburg, Department of Cardiology, Hamburg, Germany
| | - J Schirmer
- University Heart & Vascular Center Hamburg, Department for Cardiovascular Surgery, Hamburg, Germany
| | - D Westermann
- University Heart & Vascular Center Hamburg, Department of Cardiology, Hamburg, Germany
| | - H Reichenspurner
- University Heart & Vascular Center Hamburg, Department for Cardiovascular Surgery, Hamburg, Germany
| | - S Blankenberg
- University Heart & Vascular Center Hamburg, Department of Cardiology, Hamburg, Germany
| | - E Lubos
- University Heart & Vascular Center Hamburg, Department of Cardiology, Hamburg, Germany
| | - L Conradi
- University Heart & Vascular Center Hamburg, Department for Cardiovascular Surgery, Hamburg, Germany
| | - D Kalbacher
- University Heart & Vascular Center Hamburg, Department of Cardiology, Hamburg, Germany
| |
Collapse
|
5
|
Bhadra OD, Demal TJ, Schneeberger Y, Ludwig S, Waldschmidt L, Grundmann D, Voigtlaender L, Linder M, Schofer N, Blankenberg S, Reichenspurner H, Seiffert M, Conradi L, Westermann D, Schaefer A. Comparison of Two Contemporary Balloon-Expandable Transcatheter Heart Valves: Sapien 3 versus Sapien 3 Ultra. Thorac Cardiovasc Surg 2021. [DOI: 10.1055/s-0041-1725831] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
6
|
Demal TJ, Gordon C, Bhadra OD, Linder M, Ludwig S, Voigtländer L, Waldschmidt L, Schirmer J, Schofer N, Seiffert M, Blankenberg S, Reichenspurner H, Westermann D, Conradi L. Transcatheter Aortic Valve-in-Valve Implantation versus Redo Surgery: A Contemporary Comparative Analysis. Thorac Cardiovasc Surg 2021. [DOI: 10.1055/s-0041-1725666] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
7
|
Waldschmidt L, Gossling A, Ludwig S, Linder M, Voigtlaender L, Schaefer A, Bhadra O, Schirmer J, Reichenspurner H, Blankenberg S, Westermann D, Seiffert M, Conradi L, Schofer N. Prevalence and prognostic impact of left ventricular outflow tract calcification in patients with severe aortic stenosis undergoing transfemoral TAVI using second-generation devices. Eur Heart J 2020. [DOI: 10.1093/ehjci/ehaa946.2599] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Introduction
Left ventricular outflow tract (LVOT) calcification is known to be associated with adverse outcomes after TAVI in patients receiving first-generation transcatheter heart valves (THV). Second-generation THV have been shown to improve outcomes of TAVI patients. Thus, aim of this study is to assess the prevalence of LVOT calcification as well as its impact on procedural and clinical outcomes in patients with severe aortic stenosis undergoing transfemoral TAVI with second-generation THV in a real-world patient cohort.
Methods
In this retrospective single-center analysis patients receiving transfemoral TAVI with second-generation THV for the treatment of aortic stenosis (AS) between 05/2012 and 06/2018 and with adequate CT data were included (n=836). Amount of LVOT calcification was measured quantitatively from contrast-enhanced multislice CT using a dedicated software. Baseline characteristics and outcomes were compared according to presence of significant LVOT calcification (none/≤10 mm3 vs. >10 mm3). Procedural and clinical outcome were assessed in accordance with VARC-2 criteria. All-cause mortality was assessed by Kaplan-Meier method, median follow-up was 1.4 years.
Results
Significant LVOT calcification was present in 37.0% of patients. Patients with LVOT calcification were older (all results as follows without (w/o) vs. with (w) LVOT calcification: 81.4 (77.1, 84.8) vs. 82.3 (78.0, 86.3) years, p=0.006), but presented similar STS scores compared to those without LVOT calcification (5.4±4.7 vs. 5.4±3.5%, p=0.94). Moreover, patients with LVOT calcification had higher mean transvalvular gradients at baseline (30.0 (21.0, 41.0) vs. 37.0 (25.7, 47.0) mmHg, p<0.001) and higher aortic valve calcium volume (380.7 (226.8, 632.1) vs. 663.6 (364.5, 1070.3) mm3, p<0.001). There were no significant differences in rate of device success (97.0 vs. 94.2%, p=0.11), renal failure (2.6 vs. 2.3%, p=1.00), myocardial infarction (0.9 vs. 1.2%, p=1.00) or rate of permanent pacemaker implantation at 30 days after TAVI (16.6 vs. 17.2%, p=0.91). However, rate of TIA/stroke was significantly higher in patients with LVOT calcification (2.1 vs. 6.2%, p=0.0098). Furthermore, patients with LVOT calcification had a higher rate of more than mild paravalvular leakage at discharge (3.8 vs. 7.6%, p=0.033). Rate of 1 year all-cause mortality (17.8 vs. 21.2%, p=0.23) was not significantly different between both groups.
Conclusions
Significant LVOT calcification is present in a substantial proportion of patients receiving TAVI. In such patients, higher rates of cerebrovascular events and more than mild PVL occurred compared to those without significant LVOT calcification even with currently available second-generation THV. Although these findings did not translate into higher mortality rates in the present study, they underline the need for further optimization of THV technology in order to improve outcomes among all TAVI patients.
Figure 1. 1-year mortality
Funding Acknowledgement
Type of funding source: None
Collapse
Affiliation(s)
- L Waldschmidt
- The University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - A Gossling
- The University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - S Ludwig
- The University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - M Linder
- The University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - L Voigtlaender
- The University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - A Schaefer
- The University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - O Bhadra
- The University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - J Schirmer
- The University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - H Reichenspurner
- The University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - S Blankenberg
- The University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - D Westermann
- The University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - M Seiffert
- The University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - L Conradi
- The University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - N Schofer
- The University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| |
Collapse
|
8
|
Ludwig S, Pellegrini C, Gossling A, Rheude T, Waldschmidt L, Bhadra O, Linder M, Schirmer J, Seiffert M, Reichenspurner H, Blankenberg S, Westermann D, Conradi L, Joner M, Schofer N. The adverse impact of HFpEF in patients with aortic stenosis: evaluation of the H2FPEF score for risk assessment among patients with preserved ejection fraction undergoing TAVI. Eur Heart J 2020. [DOI: 10.1093/ehjci/ehaa946.2622] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
The H2FPEF score enables identification of patients with high probability of prevalent heart failure with preserved ejection fraction (HFpEF). High H2FPEF scores have proven to be associated with adverse outcome in patients with known HFpEF.
Objective
The aim of this study was to assess the prognostic impact of the H2FPEF score in patients undergoing Transcatheter Aortic Valve Implantation (TAVI) for severe aortic stenosis (AS) and preserved left ventricular ejection fraction (EF).
Methods
In this multi-centre study a total of 832 patients from two German high-volume centres, who received TAVI for severe AS and preserved EF (≥50%), were identified for calculation of the H2FPEF score. Score variables included BMI >30 kg/m2, arterial hypertension, atrial fibrillation, systolic pulmonary artery pressure >31 mmHg, age >60 years, and invasively assessed elevated LV filling pressure. Patients were dichotomized according to low (1–5 points; n=570) and high H2FPEF scores (6–9 points; n=262). Kaplan-Meier and Cox regression analyses were applied to assess the prognostic impact of the H2FPEF score. Median follow-up time was 1.08 years.
Results
Patients presenting with high H2FPEF scores had higher prevalence of moderate to severe mitral and tricuspid regurgitation compared to those with low H2FPEF scores. Stroke volume index (SVI) (Figure 1A) and mean transvalvular gradient (Pmean) consistently decreased with increasing H2FPEF score. All-cause mortality 30 days after TAVI was significantly higher in patients with high H2FPEF scores (p<0.0001). This finding was consistent both after 1 year (p<0.0001) and 3 years (p<0.0001) (Figure 1B). Multivariate analysis revealed a high H2FPEF score to be independently predictive for all-cause mortality (HR 1.62, 95% CI: 1.11–2.38, p=0.013). Among the single H2FPEF score parameters atrial fibrillation was the strongest independent predictor of adverse outcome.
Conclusion
An elevated H2FPEF score of ≥6 is independently predictive for mortality in patients with preserved EF undergoing TAVI for severe AS, which might be due to a higher proportion of paradoxical low flow low gradient AS in these patients. Our findings provide evidence that the H2FPEF score may help identify AS patients with preserved ejection fraction that are at higher risk for adverse outcome after TAVI.
Spline/SVI (A) and 3y-mortality KM (B)
Funding Acknowledgement
Type of funding source: None
Collapse
Affiliation(s)
- S Ludwig
- University Heart and Vascular Center Hamburg, Hamburg, Germany
| | - C Pellegrini
- Deutsches Herzzentrum Muenchen Technical University of Munich, Department of Cardiology, Munich, Germany
| | - A Gossling
- University Heart and Vascular Center Hamburg, Hamburg, Germany
| | - T Rheude
- Deutsches Herzzentrum Muenchen Technical University of Munich, Department of Cardiology, Munich, Germany
| | - L Waldschmidt
- University Heart and Vascular Center Hamburg, Hamburg, Germany
| | - O.D Bhadra
- University Heart & Vascular Center Hamburg, Department of Cardiovascular Surgery, Hamburg, Germany
| | - M Linder
- University Heart and Vascular Center Hamburg, Hamburg, Germany
| | - J Schirmer
- University Heart & Vascular Center Hamburg, Department of Cardiovascular Surgery, Hamburg, Germany
| | - M Seiffert
- University Heart and Vascular Center Hamburg, Hamburg, Germany
| | - H Reichenspurner
- University Heart & Vascular Center Hamburg, Department of Cardiovascular Surgery, Hamburg, Germany
| | - S Blankenberg
- University Heart and Vascular Center Hamburg, Hamburg, Germany
| | - D Westermann
- University Heart and Vascular Center Hamburg, Hamburg, Germany
| | - L Conradi
- University Heart & Vascular Center Hamburg, Department of Cardiovascular Surgery, Hamburg, Germany
| | - M Joner
- Deutsches Herzzentrum Muenchen Technical University of Munich, Department of Cardiology, Munich, Germany
| | - N Schofer
- University Heart and Vascular Center Hamburg, Hamburg, Germany
| |
Collapse
|
9
|
Ludwig S, Voigtlaender L, Ruebsamen N, Kalbacher D, Koell B, Linder M, Waldschmidt L, Schirmer J, Seiffert M, Conradi L, Schaefer U, Reichenspurner H, Blankenberg S, Westermann D, Schofer N. P3858High H2FPEF score is an independent predictor of adverse outcome in patients with severe aortic stenosis and preserved ejection fraction undergoing TAVR. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz745.0696] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
Recently, the H2FPEF score has been developed in an evidence-based approach relying on simple clinical and echocardiographic variables. It enables the identification of patients with high probability of prevalent heart failure with preserved ejection fraction (HFpEF) which is associated with a dismal prognosis. Left ventricular diastolic dysfunction, a key mechanism in HFpEF, is also a common finding in patients with severe aortic stenosis.
Objective
To assess the prognostic impact of the H2FPEF score in patients with preserved ejection fraction and severe aortic stenosis undergoing Transcatheter Aortic Valve Replacement (TAVR).
Methods
Among 1148 patients with preserved ejection fraction who received TAVR at our institution between 2013 and 2018, data for calculation of the H2FPEF score was available in 535 patients. Score variables include BMI >30 kg/m2, arterial hypertension, atrial fibrillation, pulmonary hypertension >35 mmHg, age >60 years, and elevated LV filling pressure. Patients were dichotomized according to “low” (1–5 points; n=377) and “high” H2FPEF scores (6–9; n=158). Kaplan-Meier survival curves and Cox regression analyses were used to assess the prognostic impact of H2FPEF scores. Median follow-up time was 0.3 years.
Results
TAVR patients presenting with high H2FPEF scores had higher prevalence of moderate to severe mitral regurgitation (19.4% vs. 33.6%, p<0.001) as well as tricuspid regurgitation (15.2% vs. 35.1%, p<0.001), and presented with lower stroke volume index (42.2 ml/m2 vs. 36.0 ml/m2, p<0.001) compared to those with low H2FPEF scores. All-cause mortality one year after TAVR was significantly higher in patients in the high H2FPEF score group (10.5% vs. 21.0%, p=0.0019, Figure 1). Multivariate analysis revealed a high H2FPEF score to be independently predictive for 1-year all-cause mortality (HR 2.66, 95% CI: 1.41–5.02, p=0.025). Among the single H2FPEF score variables, atrial fibrillation (HR 3.45, 95% CI: 1.86–6.40, p<0.001) and systolic pulmonary hypertension >55 mmHg (HR=2.68, 95% CI: 0.97–7.40, p=0.057) were strong independent predictors of adverse outcome.
Figure 1. All-cause mortality of patients undergoing TAVR after one year stratified by low (1–5 points) and high (6–9) H2FPEF score
Conclusion
An elevated H2FPEF score of >6 is independently predictive for mortality in patients with preserved ejection fraction undergoing TAVR for severe aortic stenosis. Our findings provide evidence that the H2FPEF score, which was meant for diagnostic use originally, is able to serve as a prognostic tool in patients with preserved ejection fraction undergoing TAVR, highlighting the adverse impact of diastolic dysfunction in patients with preserved ejection fraction and aortic stenosis.
Collapse
Affiliation(s)
- S Ludwig
- University Heart Center Hamburg, Hamburg, Germany
| | | | - N Ruebsamen
- University Heart Center Hamburg, Hamburg, Germany
| | - D Kalbacher
- University Heart Center Hamburg, Hamburg, Germany
| | - B Koell
- University Heart Center Hamburg, Hamburg, Germany
| | - M Linder
- University Heart Center Hamburg, Hamburg, Germany
| | | | - J Schirmer
- University Heart Center Hamburg, Hamburg, Germany
| | - M Seiffert
- University Heart Center Hamburg, Hamburg, Germany
| | - L Conradi
- University Heart Center Hamburg, Hamburg, Germany
| | - U Schaefer
- University Heart Center Hamburg, Hamburg, Germany
| | | | | | - D Westermann
- University Heart Center Hamburg, Hamburg, Germany
| | - N Schofer
- University Heart Center Hamburg, Hamburg, Germany
| |
Collapse
|
10
|
Waldschmidt L, Drolz A, Heimburg P, Gossling A, Schofer N, Voigtlaender L, Ludwig S, Linder M, Reichenspurner H, Blankenberg S, Schaefer U, Westermann D, Conradi L, Kluwe J, Seiffert M. P1848Prevalence and outcomes in patients with Heyde syndrome after transcatheter aortic valve implantation, a single centre experience. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz748.0599] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Introduction
Heyde syndrome is known as the association of severe aortic stenosis (AS) and recurrent gastrointestinal bleeding (GIB) from angiodysplasia. To date only few data exist regarding the prevalence of Heyde syndrome and results after transcatheter aortic valve implantation (TAVI) for the treatment of AS.
Purpose
We sought to evaluate the prevalence of Heyde syndrome in a routine clinical cohort of patients undergoing TAVI and analyze the effectiveness of treatment of AS regarding recurrent GIB in these patients.
Methods
We conducted a retrospective single-center analysis of 2545 consecutive patients who underwent TAVI for the treatment of AS in 2008–2017. Patients with a history of GIB were identified. The diagnosis of Heyde syndrome was defined as a clinical triad of presence of severe AS, a history of recurrent GIB, and an endoscopic diagnosis of angiodysplasia. GIB of unknown origin or related to other causes was defined as bleeding unrelated to angiodysplasia. Clinical outcomes of patients with Heyde syndrome were evaluated with emphasis on bleeding complications and recurrence of GIB.
Results
A history of GIB prior to TAVI was detected in 190 patients (7.5%) of the TAVI cohort. Among them, 143 patients had a GIB unrelated to angiodysplasia (5.6%) and 47 patients (1.8%) were diagnosed with Heyde syndrome. Median age and STS-PROM were 80.7 (75.3, 84.0) years and 4.7 (2.7, 9.0) respectively in Heyde patients. TAVI was successfully performed in all cases (66% endovascular access, 34% transapical access). The effective orifice areas increased from 0.8±0.1 cm2 to 2.1±0.5 cm2. Periprocedural major/life-threatening bleeding was found in 6 patients (12.8%), mainly access-related and none due to GIB. In 51% of Heyde-patients transfusion of 4.5±5.7 packed red blood cells was required during the index hospitalisation. During a mean follow-up of 12 months, recurrent GIB after TAVI was detected in 32% of patients with Heyde syndrome. In contrast only 18% of patients with GIB unrelated to angiodysplasia (Non-Heyde) had recurrent GIB after TAVI. In patients diagnosed with Heyde syndrome and recurrent GIB after TAVI the rate of residual mild or moderate paravalvular regurgitation was higher compared to those with an unremarkable course (73% vs. 37%, p=0.045).
Figure 1. 1-year Follow-Up
Conclusions
A relevant number of patients presenting for treatment of AS can be diagnosed with Heyde syndrome. In these patients TAVI can be successfully performed with moderate incidence of periprocedural bleeding complications but significant transfusion rates. Regardless of successful treatment of AS, recurrent GIB was detected in a significant number of Heyde patients during follow-up. The possible association with residual paravalvular regurgitation requires further investigation to improve treatment options in patients with Heyde syndrome.
Collapse
Affiliation(s)
- L Waldschmidt
- The University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - A Drolz
- The University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - P Heimburg
- The University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - A Gossling
- The University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - N Schofer
- The University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - L Voigtlaender
- The University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - S Ludwig
- The University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - M Linder
- The University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - H Reichenspurner
- The University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - S Blankenberg
- The University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - U Schaefer
- The University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - D Westermann
- The University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - L Conradi
- The University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - J Kluwe
- The University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - M Seiffert
- The University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| |
Collapse
|